Rosuvastatin and progression of atherosclerosis

Abstract

Technological advances in arterial wall imaging have provided the opportunity to evaluate the impact of medical therapies on the progression of atherosclerosis in vivo. Arterial imaging has been extensively utilized to determine the impact of high-dose statin therapy. Using multiple imaging modalities in the carotid and coronary territories, rosuvastatin has been demonstrated to have a beneficial impact across the spectrum of cardiovascular risk. The impact of modifying levels of atherogenic lipids, HDL and markers of inflammation will be reviewed.

Keywords::

• atherosclerosis
• imaging
• rosuvastatin

Financial & competing interests disclosure

Stephen Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough and Takeda, consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, Takeda, Roche, Novo-Nordisk, LipoScience and Anthera and research support from AstraZeneca and Lipid Sciences. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.